Download this measure in English. BACK FACIT-Dyspnea Item Bank English Downloads Not available

View all available languages for this measure. BACK FACIT-Dyspnea Languages Arabic Afrikaans Bengali Bulgarian Chinese - Simplified Chinese - Traditional Croatian Czech Danish Dutch English Finnish French Georgian German Greek Gujarati Hebrew Hindi Hungarian Italian Japanese Kannada Korean Latvian Lithuanian Malay Malayalam Marathi Norwegian Polish Portuguese Punjabi Romanian Russian Sepedi Serbian Sesotho Setswana Slovak Slovene Spanish Swahili Swedish Tagalog Tamil Telugu Thai Turkish Ukrainian Urdu Vietnamese Xhosa Zulu

NFLSI-17 Functional Assessment of Cancer Therapy Lung Cancer Symptom Index – 17 Item Version For patients with Lung cancer; a FACT/NCCN-Lung Symptom Index LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The NCCN/FACT Lung Cancer Symptom Index-17 (NFLSI-17) is a brief symptom index for patients with advanced lung cancer. It was developed with input from 50 patients with advanced lung cancer who were recruited from National Comprehensive Cancer Network (NCCN) member institutions and community support agencies, along with 10 physician experts who were recruited from NCCN institutions. Patients reported symptoms associated with their disease in an open-ended format and then completed a checklist of symptoms, rating their 5 most important symptoms. Patient and provider ratings of symptom importance were tabulated to construct NFLSI-17. Patients also completed the Functional Assessment of Cancer Therapy-Lung (FACT-L), which was used to preliminarily validate the NFLSI-17. Based on this input, the NFLSI-17 is composed of 17 priority symptoms, 11 that are disease related, 3 that are treatment related, and 3 that are related to general functional well-being. Data on 15 of 17 NFLSI-17 symptoms showed good internal consistency (alpha = 0.74) and strong association with the FACT-L total and most subscale scores (r = 0.42-0.92). MEASURE NAME: Functional Assessment of Cancer Therapy Lung Cancer Symptom Index – 17 Item Version (NFLSI-17) VERSION: 2 NUMBER OF ITEMS: 17 PATIENT POPULATION: Lung cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Disease-Related Symptoms – Physical, Disease-Related Symptoms – Emotional, Treatment Side-Effects, Function/Well-Being TIME FOR COMPLETION: 5-10 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores and total scores available. RELATED MEASURES: FACT-L , FLSI , FLSI-12 , FACT-LCS , FACT-PSI DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the NFLSI-17 can be obtained by registering for permission. Users are not permitted to translate the NFLSI-17 without permission from FACIT.org. Permission from FACIT.org to translate the NFLSI-17 may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Cella, D., Paul, D., Yount, S., Winn, R., Chang, C-H, Banik, D., & Weeks, J. What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Investigation 2003; 21(4): 526-535. doi: 10.108/CNV-120022366. Cella, D., Rosenbloom, S., Beaumont, J., Yount, J., Paul, D., Hampton, D., Abernethy, A., Jacobsen, P., Syrjala, K., & Von Roenn, J. Development and validation of 11 symptom indexes to evaluate response to chemotherapy for advanced cancer. Journal of the National Comprehensive Cancer Network; 2011; 9(3): 268-278. doi: 10.6004/jnccn.2011.0026. Rosenbloom, S., Yount, S., Yost, K., Hampton, D., Paul, D., Abernethy, A., Jacobsen, P., Syrjala, K., Von Roenn, J., & Cella, D. Development and validation of eleven symptom indices to evaluate response to chemotherapy for advanced cancer: Measurement compliance with regulatory demands. Farquhar, I., Summers, K., Sorkin, A. (Eds.). The Value of Innovation: Impacts on Health, Life Quality and Regulatory Research. Emerald Group Publishing Inc. 2007; 16: 53-66. doi: 10.1016/S0194-3960(08)16003-6. Yount, S., Beaumont, J., Rosenbloom, S., Cella, D., Patel, J., Hensing, T., Jacobsen, P., Syrjala, K., & Abernethy, A. A brief symptom index for advanced lung cancer. Clinical Lung Cancer 2012; 13(1): 14-23. doi: 10.1016/j.cllc.2011.03.033. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACT-L Functional Assessment of Cancer Therapy – Lung LEARN MORE FLSI Functional Assessment of Cancer Therapy Lung Cancer Symptom Index - 6 Item Version LEARN MORE FLSI-12 Functional Assessment of Cancer Therapy Lung Cancer Symptom Index - 12 Item Version LEARN MORE

View all available languages for this measure. BACK NFLymSI-18 Languages Afrikaans Arabic Bulgarian Simplified Chinese Traditional Chinese Czech Danish Dutch English Finnish French German Georgian Greek Hebrew Hungarian Italian Japanese Korean Lithuanian Malay Norwegian Polish Portuguese Romanian Russian Serbian Sesotho Slovak Spanish Swedish Tamil Tagalog Thai Turkish Ukrainian Vietnamese

Download this measure in English. BACK FACT-CSI English Downloads Download PDF - FACT-CSI Download DOC - FACT-CSI Download PDF - FACT-GINET Download DOC - FACT-GINET Download PDF - FACT-LNET Download DOC - FACT-LNET Download PDF - FACT-PNET Download DOC - FACT-PNET

Download this measure in English. BACK PROMIS Item Bank v1.0 Dyspnea Severity English Downloads Download PDF Download DOC

Download this measure in English. BACK BESS English Downloads Download PDF Download DOC

Download this measure in English. BACK PRAI English Downloads Download PDF Download DOC

FLSI Functional Assessment of Cancer Therapy Lung Cancer Symptom Index - 6 Item Version For patients with Lung cancer; A FACT-Lung Symptom Index (a subset of FACT-L containing 6 items) LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview Below are the details for the FLSI measure: MEASURE NAME: Functional Assessment of Cancer Therapy Lung Cancer Symptom Index - 6 Item Version (FLSI) VERSION: 4 NUMBER OF ITEMS: 6 PATIENT POPULATION: Lung cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: Response scale: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Lung cancer symptom index TIME FOR COMPLETION: Less than 5 minutes SCORING: Manual scoring template, some items are reverse scored. Total scores available. SAS/SPSS algorithms available. RELATED MEASURES: FACT-L , NFLSI-17 , FLSI-12 , FACT-PSI , FACT-LCS DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FLSI can be obtained by registering for permission. Users are not permitted to translate the FLSI without permission from FACIT.org. Permission from FACIT.org to translate the FLSI may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Cella, D., Paul, D., Yount, S., Winn, R., Chang, C-H, Banik, D., & Weeks, J. What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Investigation 2003; 21(4): 526-535. doi: 10.108/CNV-120022366. Cella, D., Rosenbloom, S., Beaumont, J., Yount, J., Paul, D., Hampton, D., Abernethy, A., Jacobsen, P., Syrjala, K., & Von Roenn, J. Development and validation of 11 symptom indexes to evaluate response to chemotherapy for advanced cancer. Journal of the National Comprehensive Cancer Network; 2011; 9(3): 268-278. doi: 10.6004/jnccn.2011.0026. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACT-L Functional Assessment of Cancer Therapy – Lung LEARN MORE NFLSI-17 National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Lung Cancer Symptom Index - 17 Item Version LEARN MORE FLSI-12 Functional Assessment of Cancer Therapy Lung Cancer Symptom Index - 12 Item Version LEARN MORE

Download this measure in English. BACK FACIT-Sp-12 English Downloads Download PDF Download DOC

Download this measure in English. BACK FACT-V English Downloads Download PDF Download DOC

Download scoring documents for this measure. BACK FOSI Scoring Downloads Download DOC